CLINICAL TRIALS PROFILE FOR ACAMPROSATE CALCIUM
✉ Email this page to a colleague
All Clinical Trials for ACAMPROSATE CALCIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00571103 ↗ | Acamprosate in the Treatment of Pathological Gambling | Completed | Forest Laboratories | Phase 4 | 2007-10-01 | The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder. |
| NCT00571103 ↗ | Acamprosate in the Treatment of Pathological Gambling | Completed | University of Nebraska | Phase 4 | 2007-10-01 | The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder. |
| NCT00571103 ↗ | Acamprosate in the Treatment of Pathological Gambling | Completed | University of Iowa | Phase 4 | 2007-10-01 | The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder. |
| NCT00591565 ↗ | An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants | Completed | Forest Laboratories | N/A | 2006-06-01 | This study is designed to evaluate anxious patients who are only partially responsive to typical SSRI or SNRI anti-anxiety medication therapy. Patients who are less than 50% anxiety-alleviated on their SSRI medication will be asked to join the study and be placed on Acamprosate as well. This type of add-on therapy is common in outpatient psychiatric care. This is a rater-blinded, patient open-label, non-placebo prospective study, where all subjects will receive Acamprosate for 8 weeks. This study would be the first to date in this treatment-resistant patient population, as the investigators will utilize the a comprehensive set of rating scales in order to best categorize patient responses in regards to anxiety, co-occurring depression, sleep disorders, alcohol use, and social functioning with this drug. This study may be pivotal to the initiation of future double-blind, placebo-controlled studies for this agent |
| NCT00591565 ↗ | An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants | Completed | State University of New York - Upstate Medical University | N/A | 2006-06-01 | This study is designed to evaluate anxious patients who are only partially responsive to typical SSRI or SNRI anti-anxiety medication therapy. Patients who are less than 50% anxiety-alleviated on their SSRI medication will be asked to join the study and be placed on Acamprosate as well. This type of add-on therapy is common in outpatient psychiatric care. This is a rater-blinded, patient open-label, non-placebo prospective study, where all subjects will receive Acamprosate for 8 weeks. This study would be the first to date in this treatment-resistant patient population, as the investigators will utilize the a comprehensive set of rating scales in order to best categorize patient responses in regards to anxiety, co-occurring depression, sleep disorders, alcohol use, and social functioning with this drug. This study may be pivotal to the initiation of future double-blind, placebo-controlled studies for this agent |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACAMPROSATE CALCIUM
Condition Name
Clinical Trial Locations for ACAMPROSATE CALCIUM
Trials by Country
Clinical Trial Progress for ACAMPROSATE CALCIUM
Clinical Trial Phase
Clinical Trial Sponsors for ACAMPROSATE CALCIUM
Sponsor Name
